68 / 88
68
Scientific Programme /
Thursday, 22 June 2017
WFSBP 2017
THU
P-21
POSTER TOUR
13:00–14:30
Congress Hall A 1
Schizophrenia 3
Chair:
Janusz Rybakowski, Poland
001
Variability of 128 schizophrenia-associated gene
variants across distinct ethnic populations
Kazutaka Ohi, Japan
T. Shimada, T. Yasuyama, T. Uehara, Y. Kawasaki
002
Association study between Dysbindin gene and
schizophrenia in a Korean population
Kyu-Young Lee, Germany
E.-J. Joo
003
Low methylation rates of dopamine receptor D2
gene promoter sites in Japanese schizophrenia subjects
Yuta Yoshino, Japan
K. Kawabe, Y. Mori, K. Yamazaki, J.-I. Iga, S.-I. Ueno
005
Gender-specific associations of the brain-derived
neurotrophic factor Val66Met polymorphism with neu-
rocognitive and clinical features in schizophrenia
Sung-Wan Kim, Republic of Korea
Y.-H. Lee, T.-Y. Yoo, J.-Y. Lee, J.-M. Kim, I.-S. Shin, J.-S. Yoon
006
Sequencing of neurotrophic tyrosine receptor
kinase 1 gene region in Armenian schizophrenia patients
Roksana Zakharyan, Armenia
A. Arakelyan
007
Clinical characteristics of formal thought disorder
in schizophrenia
Ho-Seon Lee, Republic of Korea
S.-C. Park
009
SorCS1 regulates inhibitory networks and gamma-
oscillations – a link to schizophrenia?
Peter Lund Ovesen, Denmark
U. Bølcho, K. M. Pedersen, S. Mølgaard Jensen, S. Glerup,
M. M. Holm, A. Nykjær
010
Impact of familial loading on prefrontal activation
in major psychiatric disorders: A Near-Infrared
Spectroscopy (NIRS) study
Kazutaka Ohi, Japan
T. Shimada, H. Kihara, T. Yasuyama, K. Sawai, K. Oshima,
H. Okubo, Y. Nitta, T. Uehara, Y. Kawasaki
011
Total and high-affinity-state dopamine D2 recep-
tors in the striatum of antipsychotic-free patients with
schizophrenia: A PET study with [11C] raclopride and
[11C] MNPA
Manabu Kubota, Japan
T. Nagashima, H. Takano, F. Kodaka, H. Fujiwara,
K. Takahata, S. Moriguchi, Y. Kimura, M. Higuchi,
Y. Okubo, H. Takahashi, T. Suhara
013
Brain anatomy of symptom stratification in schizo-
phrenia: A voxel based morphometry study
Giuseppe Delvecchio, Italy
A. Lorandi, C. Perlini, M. Barillari, M. Ruggeri,
A. C. Altamura, M. Bellani, P. Brambilla
014
White matter correlates of impaired gesture per-
formance and recognition in schizophrenia
Petra Viher, Switzerland
P. Savadjiev, K. Stegmayer, N. Makris, S. Karmacharya,
A. Federspiel, S. Bohlhalter, T. Vanbellingen, R. Wiest,
M. E. Shenton, W. K. Strik, M. Kubicki, S. Walther
015
Is the perception of language cues different in
schizophrenia?: A pilot study
Marie Bendova, Czech Republic
Y. Zaytseva, M. Kolarova, M. Mojzisek, J. Rydlo, R. Gaspar,
F. Spaniel
016
Amelioration of abnormal beliefs in subjects at
ultra high-risk for psychosis linked to longitudinal in-
crease in ventral striatal function during salience
processing
André Schmidt, Switzerland
M. Antoniades, P. Allen, A. Egerton, C. Chaddock,
S. Borgwardt, P. Fusar-Poli, J. Roiser, O. Howes,
P. McGuire
017
The N-Methyl D-Aspartate glutamate receptor
antagonist ketamine disrupts the functional state of
the corticothalamic pathway
Paul Anderson, The Netherlands
N. Jones, T. O'Brien, D. Pinault
018
Impact of trauma on negative symptoms of schizo-
phrenia
Ombline Bolloré, France
D. Fouques, C. Isaac, D. Januel
020
Formal thought disorder in schizophrenia patients:
Gender differences
Joon-Ho Choi, Republic of Korea
J.-E. Park, S.-C. Park
021
The validity and sensitivity of PANSS-6 in the Clini-
cal Antipsychotic Trials of Intervention Effectiveness
(CATIE) study
Søren Dinesen Østergaard, Denmark
L. Foldager, O. Mors, P. Bech, C. U. Correll
022
Novel strategies of treatment of mental disorders
based on D-cell hypothesis
Keiko Ikemoto, Japan